SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Receives 510(k) Clearance of Technological Advancements and an Expanded Intended Patient Population for the SPRINT® PNS System
February 03, 2023 15:32 ET | SPR Therapeutics, Inc.
CLEVELAND, Feb. 03, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Debuts Occipital Nerve Stimulation Data at ASRA 2022
November 17, 2022 09:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Nov. 17, 2022 (GLOBE NEWSWIRE) -- At the 21st Annual American Society of Regional Anesthesia (ASRA) Pain Medicine Meeting in Orlando, SPR Therapeutics is highlighting five new data sets...
SPR Therapeutics LOGO 361 TM.jpg
Real-World Retrospective Review of Axial Neck Pain Relief Following Peripheral Nerve Stimulation of Cervical Medial Branch Nerves
September 21, 2022 15:02 ET | SPR Therapeutics, Inc.
- Data presented at Pacific Spine Pain Society annual meeting - CLEVELAND, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics shared data on the use of peripheral nerve stimulation (PNS) to...
ML2pt0_strengthimage_press_v1
Next Generation MicroLead 2.0 Now Available with the SPRINT® PNS System
September 06, 2022 08:00 ET | SPR Therapeutics, Inc.
CLEVELAND, Sept. 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today the formal introduction of its new MicroLead™ 2.0, designed to enhance the performance of the SPRINT® PNS System. As a...
SPR Therapeutics LOGO 361 TM.jpg
Peripheral Nerve Stimulation Pioneer Dr. Marc Huntoon Joins SPR Therapeutics as Director of Medical Affairs
August 02, 2022 16:23 ET | SPR Therapeutics, Inc.
CLEVELAND, Aug. 02, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics is proud to announce the addition of Dr. Marc Huntoon to the company as Director of Medical Affairs. In this role, he will provide...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics to Present Clinical Trial and Real-World Findings at ASPN 2022
July 14, 2022 10:54 ET | SPR Therapeutics, Inc.
CLEVELAND, July 14, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced today that two presentations highlighting SPRINT® PNS in treating chronic pain will be featured at the American Society of...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Named a Top Workplace
June 26, 2022 11:00 ET | SPR Therapeutics, Inc.
CLEVELAND, June 26, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics has been awarded a Top Workplaces 2022 honor by cleveland.com and The Plain Dealer. The award is based on employee feedback gathered...
SPR Therapeutics LOGO 361 TM.jpg
SPR Therapeutics Announces 10,000th SPRINT PNS Procedure for Patients Suffering from Life-altering Pain
May 12, 2022 09:00 ET | SPR Therapeutics, Inc.
CLEVELAND, May 12, 2022 (GLOBE NEWSWIRE) -- Cleveland based medical device company SPR Therapeutics today announced a key milestone with the 10,000th patient treated using the SPRINT® PNS System....
SPR Therapeutics LOGO 361 TM.jpg
Real-world Study of SPRINT 60-day Peripheral Nerve Stimulation (PNS) Corroborates Published Clinical Study Results
May 06, 2022 09:24 ET | SPR Therapeutics, Inc.
CLEVELAND, May 06, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced the publication of a study that evaluated the real-world impact of 60-day peripheral nerve stimulation (PNS) in the management...
SPR Therapeutics LOGO 361 TM.jpg
Prolonged Temporary Neurostimulation Treatment Period Offered by the SPRINT® PNS System May Optimize Pain Management Care Pathway While Reducing Healthcare Costs
March 15, 2022 10:31 ET | SPR Therapeutics, Inc.
CLEVELAND, March 15, 2022 (GLOBE NEWSWIRE) -- SPR Therapeutics announced publication of a study in the Journal of Pain Research demonstrating how a longer initial treatment period may better...